NHD Global
Metabolic & Weight Loss · Source-reviewed dossier
Source-Reviewed Research Dossier
Cagrilintide + Semaglutide Blend combines an amylin analogue and a GLP-1 receptor agonist. Published CagriSema trials evaluate a sponsor-controlled combination in defined populations; those results cannot be transferred to a third-party research blend.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2025 randomized trial reported body-weight outcomes for coadministered cagrilintide and semaglutide.
The intervention was a regulated clinical-development formulation, not this catalog blend.
Read the primary studyA companion study evaluated the combination in adults with overweight or obesity and type 2 diabetes.
Population and protocol differences prevent pooling results without qualification.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Multi-component research blend · 5 mg/vial catalog presentation · 10-vial pack · component identity and ratio controlled by product specification.
Request by lot: CoA, component identity and purity
Multi-component research blend · 10 mg/vial catalog presentation · 10-vial pack · component identity and ratio controlled by product specification.
Request by lot: CoA, component identity and purity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
The intervention was a regulated clinical-development formulation, not this catalog blend.
View primary recordPopulation and protocol differences prevent pooling results without qualification.
View primary recordThird-party publications selected for direct relevance.
N Engl J Med. 2025. PMID 40544433.
N Engl J Med. 2025. PMID 40544432.
Concise answers for researchers comparing identity, evidence and catalog variants.
Cagrilintide + Semaglutide Blend combines an amylin analogue and a GLP-1 receptor agonist. Published CagriSema trials evaluate a sponsor-controlled combination in defined populations; those results cannot be transferred to a third-party research blend.
Large randomized combination trials have reported outcomes, but catalog-lot identity, ratio, purity and formulation remain separate quality questions.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
A clean comparison of cagrilintide, semaglutide and the studied CagriSema combination, including 2025–2026 phase 3 records and limits on transferring evidence.
Updated August 28, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: CS5 · 5 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
